Department of Dermatology, Multicultural Dermatology Center, Henry Ford Hospital, Detroit, Michigan; Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Department of Dermatology, Multicultural Dermatology Center, Henry Ford Hospital, Detroit, Michigan.
J Am Acad Dermatol. 2017 Aug;77(2):318-327. doi: 10.1016/j.jaad.2017.01.056. Epub 2017 May 11.
Persistence of pigmentation after a melanocyte-keratinocyte transplantation procedure (MKTP) is an important consideration for efficacy.
We sought to determine long-term repigmentation of MKTP in vitiligo and other leukodermas.
A retrospective review of electronic medical records was conducted for all MKTPs performed at Henry Ford Hospital between January 2009 and April 2014. Repigmentation was assessed by a 5-point grading scale (poor to excellent) and Vitiligo Area Scoring Index (VASI).
One hundred patients had MKTP performed at 236 anatomically-based lesions (ABLs); 63 patients with 157 ABLs had long-term data available (12-72 months; median, 24 months). Segmental vitiligo, nonsegmental vitiligo, and physical leukoderma demonstrated improvement in VASI scores: -75.6 ± 24.6%, -59.2 ± 36.6%, and -32.4 ± 33.5%, respectively. In vitiligo, at 24, 48, and 72 months after MKTP, 53%, 64%, and 53% of ABLs, respectively, maintained >75% repigmentation. Skin phototype, age, and anatomic location of ABLs had no significant effect on the outcome of treatment.
Limitations of the study include the retrospective design with uncontrolled, postoperative adjuvant treatments and inconsistent compliance to scheduled follow-up evaluations.
MKTP provides satisfactory long-term repigmentation in the majority of appropriately selected patients with leukoderma. MKTP can maintain repigmentation for at least 72 months.
黑色素细胞-角质形成细胞移植术（MKTP）后色素沉着的持久性是疗效的一个重要考虑因素。
我们旨在确定 MKTP 在白癜风和其他色素减退症中的长期复色情况。
对 2009 年 1 月至 2014 年 4 月在亨利福特医院进行的所有 MKTP 进行回顾性电子病历审查。通过 5 分制评分（差到优）和白癜风面积评分指数（VASI）评估复色情况。
100 例患者在 236 个解剖基础病变（ABL）中进行了 MKTP；63 例患者（157 个 ABL）有长期数据（12-72 个月；中位数，24 个月）。节段性白癜风、非节段性白癜风和物理性色素减退症的 VASI 评分分别改善：-75.6±24.6%、-59.2±36.6%和-32.4±33.5%。在白癜风中，MKTP 后 24、48 和 72 个月，分别有 53%、64%和 53%的 ABL 保持>75%的复色。皮肤光型、年龄和 ABL 的解剖位置对治疗结果没有显著影响。
研究的局限性包括回顾性设计，术后辅助治疗不受控制，以及对定期随访评估的不一致性。
MKTP 为大多数适当选择的色素减退症患者提供了令人满意的长期复色效果。MKTP 可以维持至少 72 个月的复色。
